BioMedNewsBreaks — Astrotech Corp. (NASDAQ: ASTC) Subsidiary Partners with Multistate Testing Lab to Market Proprietary AgLAB Solutions

Astrotech (NASDAQ: ASTC), an innovative science and technology company, and its subsidiary, AgLAB, have entered into a master lease agreement with SC Labs; the companies are working together to jointly market the AgLAB 1000-D2(TM) mass spectrometer and the AgLAB Maximum Value Process testing method to SC Labs customers. AgLAB has pioneered applications featuring the Astrotech Mass Spectrometer Technology that specifically target the hemp and cannabis markets while SC Labs, one of the largest multistate cannabis and hemp-testing labs in the United States, delivers industry-leading, science-based innovations in cannabis and hemp testing. The partnership between the two entities extends SC Labs’ analytical services directly into its clients’ production spaces by offering AgLAB’s solutions that provide real-time feedback for optimizing distillation efficiency. AgLAB noted that the AgLAB 1000 product development involves a high degree of risk and uncertainty with no guarantee that any new product will be successfully developed. “We are thrilled to announce the agreement between AgLAB and SC Labs,” said Astrotech CEO and CTO Thomas B. Pickens III in the press release. “Working together, SC Labs’ customers gain access to our AgLAB MVP solution for use directly in their production facilities. We anticipate the AgLAB MVP method will improve customers ending-weight yields by an average of 20%, and these gains should go directly to their bottom line.”

To view the full press release, visit https://ibn.fm/FebWy

About Astrotech Corp.

Astrotech is a mass-spectrometry company that launches, manages and commercializes scalable companies based on its innovative core technology through its wholly owned subsidiaries. 1st Detect develops, manufactures and sells trace detectors for use in the security and detection market. AgLAB develops and sells chemical analyzers for use in the agriculture market. BreathTech is developing a breath-analysis tool to screen for volatile organic compounds that could indicate bodily infections and compromised conditions. Pro-Control is developing the mass-spectrometry technology for use in chemical manufacturing processes. Astrotech is headquartered in Austin, Texas. For more information, please visit www.AstrotechCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to ASTC are available in the company’s newsroom at https://ibn.fm/ASTC

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN